 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...1112131415161718192021...2223» |
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Combination therapy: Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies (clinicaltrials.gov) - Jan 29, 2018
P1/2, N=58, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Dec 2017 --> Dec 2018
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Enrollment open: KELLY: Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (clinicaltrials.gov) - Jan 18, 2018
P2, N=44, Recruiting, Sponsor: MedSIR
Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- | Korlym (mifepristone) / Corcept Therap
Trial completion, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Jan 17, 2018
P1, N=37, Completed, Sponsor: Corcept Therapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Jan 17, 2018
P1/2, N=21, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> Oct 2018
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Jan 12, 2018
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Surgery, Metastases: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 12, 2018
P2, N=21, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| Talzenna (talazoparib) / Pfizer
New P3 trial, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Dec 29, 2017
P3, N=429, Recruiting, Sponsor: BioMarin Pharmaceutical
- | Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
New P2 trial, PD(L)-1 Biomarker, IO biomarker: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Dec 29, 2017
P2, N=78, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment change, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Dec 22, 2017
P3, N=302, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2017 --> Dec 2018 N=2128 --> 302
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Enrollment change, Trial termination: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) (clinicaltrials.gov) - Dec 20, 2017
P2, N=43, Terminated, Sponsor: German Breast Group
N=2128 --> 302 N=80 --> 43 | Active, not recruiting --> Terminated; very slow patient recruitment and concerns about the actuality of the study design
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: E-SPEC: Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer (clinicaltrials.gov) - Dec 19, 2017
P=N/A, N=120, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
N=80 --> 43 | Active, not recruiting --> Terminated; very slow patient recruitment and concerns about the actuality of the study design Recruiting --> Active, not recruiting
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Dec 5, 2017
P2, N=58, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Enrollment open, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 4, 2017
P3, N=345, Recruiting, Sponsor: Synthon Biopharmaceuticals BV
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
New P1 trial: Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - Dec 4, 2017
P1b, N=16, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- |||| Halaven (eribulin mesylate) / Eisai
Enrollment open, Enrollment change: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Nov 7, 2017
P1b/2, N=150, Recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | N=107 --> 150
- | Halaven (eribulin mesylate) / Eisai
New P2 trial: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) (clinicaltrials.gov) - Nov 6, 2017
P2, N=16, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Oct 27, 2017
P1, N=18, Recruiting, Sponsor: Tom Badgett
Active, not recruiting --> Recruiting | N=107 --> 150 Trial primary completion date: Jun 2017 --> Jun 2019
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2017 --> Jun 2019 Trial primary completion date: Aug 2007 --> Dec 2017
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer (clinicaltrials.gov) - Oct 25, 2017
P2, N=60, Recruiting, Sponsor: University of Washington
Trial primary completion date: Aug 2007 --> Dec 2017 Trial primary completion date: Feb 2018 --> Aug 2018
- |||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment open, Trial initiation date, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Oct 20, 2017
P3, N=328, Recruiting, Sponsor: Immunomedics, Inc.
Trial primary completion date: Feb 2018 --> Aug 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Oct 2017
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Oct 19, 2017
P1, N=37, Active, not recruiting, Sponsor: Corcept Therapeutics
Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Oct 2017 Trial primary completion date: Sep 2017 --> Dec 2017
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Oct 16, 2017
P2, N=118, Active, not recruiting, Sponsor: Asan Medical Center
Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Sep 2018 --> Sep 2019
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Oct 16, 2017
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2018 --> Sep 2019 Trial primary completion date: Dec 2017 --> Aug 2007
- | veliparib (ABT-888) / AbbVie, Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial withdrawal, BRCA Biomarker, Metastases: Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients (clinicaltrials.gov) - Oct 10, 2017
P2, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center at San Antonio
Trial primary completion date: Dec 2017 --> Aug 2007 N=30 --> 0 | Not yet recruiting --> Withdrawn
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Oct 9, 2017
P1, N=45, Recruiting, Sponsor: City of Hope Medical Center
N=30 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2017 --> Dec 2018
- Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial termination, Metastases: Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer (clinicaltrials.gov) - Oct 5, 2017
P=N/A, N=23, Terminated, Sponsor: Centre Oscar Lambret
Trial primary completion date: Dec 2017 --> Dec 2018 N=38 --> 23 | Recruiting --> Terminated; Lack of enrollment
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Oct 3, 2017
P1b/2, N=107, Active, not recruiting, Sponsor: Eisai Inc.
N=38 --> 23 | Recruiting --> Terminated; Lack of enrollment Trial primary completion date: Oct 2017 --> Nov 2018
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) (clinicaltrials.gov) - Sep 25, 2017
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Oct 2017 --> Nov 2018 Trial primary completion date: Aug 2018 --> Dec 2018
- |||||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: EMERALD: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (clinicaltrials.gov) - Sep 18, 2017
P3, N=480, Recruiting, Sponsor: Japan Breast Cancer Research Group
Trial primary completion date: Aug 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- ||||| Talzenna (talazoparib) / Pfizer
Enrollment closed, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Sep 12, 2017
P3, N=442, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial: EMERALD: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (clinicaltrials.gov) - Aug 29, 2017
P3, N=480, Not yet recruiting, Sponsor: Japan Breast Cancer Research Group
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion, Trial primary completion date, Combination therapy, Metastases: Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer (clinicaltrials.gov) - Aug 28, 2017
P1/2, N=92, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> May 2015
- |||||||||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
New P3 trial, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 24, 2017
P3, N=345, Not yet recruiting, Sponsor: Synthon Biopharmaceuticals BV
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, PD(L)-1 Biomarker, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Aug 17, 2017
P2, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> May 2015 Not yet recruiting --> Recruiting
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Aug 16, 2017
P1b/2, N=107, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Oct 2017
- ||| Halaven (eribulin mesylate) / Eisai
New trial, Metastases: Halaven Patient Registry (Metastatic Breast Cancer, MBC) (clinicaltrials.gov) - Aug 9, 2017
P=N/A, N=500, Recruiting, Sponsor: Chang Gung Memorial Hospital
- ||||| Halaven (eribulin mesylate) / Eisai
New P1/2 trial, Combination therapy: Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors (clinicaltrials.gov) - Aug 9, 2017
P1/2, N=86, Recruiting, Sponsor: Eisai Inc.
- Halaven (eribulin mesylate) / Eisai
Enrollment closed, Metastases: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Aug 9, 2017
P=N/A, N=8, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jun 2017 --> Oct 2017 Recruiting --> Active, not recruiting
- ||| Halaven (eribulin mesylate) / Eisai, Turalio (pexidartinib) / Daiichi Sankyo
Enrollment closed, Trial primary completion date, Metastases: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Aug 8, 2017
P1/2, N=68, Active, not recruiting, Sponsor: Hope Rugo, MD
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Feb 2017
- |||||| Talzenna (talazoparib) / Pfizer
Enrollment open, BRCA Biomarker, PARP Biomarker, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Aug 1, 2017
P3, N=429, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Feb 2017 Active, not recruiting --> Recruiting
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Jul 25, 2017
P1, N=37, Active, not recruiting, Sponsor: Corcept Therapeutics
Active, not recruiting --> Recruiting Trial primary completion date: Mar 2017 --> Sep 2017
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
New P2 trial: KELLY: Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (clinicaltrials.gov) - Jul 19, 2017
P2, N=44, Not yet recruiting, Sponsor: MedSIR
- | Trial primary completion date, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Jul 6, 2017
P2, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Jun 2017 --> Jun 2018
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 2, 2017
P2, N=58, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: May 2017 --> Oct 2017
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
New P2 trial, PD(L)-1 Biomarker, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Jun 27, 2017
P2, N=33, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: HAL03T: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 27, 2017
P=N/A, N=160, Recruiting, Sponsor: Eisai Co., Ltd.
Trial primary completion date: May 2017 --> Oct 2017 Trial primary completion date: Jun 2017 --> Nov 2018
- |||| Margenza (margetuximab-cmkb) / MacroGenics
Trial primary completion date: SOPHIA: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Jun 26, 2017
P3, N=530, Recruiting, Sponsor: MacroGenics
Trial primary completion date: Jun 2017 --> Nov 2018 Trial primary completion date: Jul 2017 --> Mar 2020
- ||| Xpovio (selinexor) / Karyopharm
Enrollment open, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Jun 21, 2017
P1, N=588, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2017 --> Mar 2020 Active, not recruiting --> Recruiting | N=142 --> 588
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 (clinicaltrials.gov) - Jun 20, 2017
P2, N=162, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting | N=142 --> 588 Trial primary completion date: Aug 2018 --> Aug 2019
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: EMEG-E-01: Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin (clinicaltrials.gov) - Jun 20, 2017
P=N/A, N=120, Recruiting, Sponsor: Centre Georges Francois Leclerc
Trial primary completion date: Aug 2018 --> Aug 2019 Trial primary completion date: May 2017 --> Jun 2018